Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy
Launched by UNIVERSITY HOSPITAL BIRMINGHAM · Jul 10, 2007
Trial Information
Current as of June 23, 2025
Completed
Keywords
ClinConnect Summary
Background:
Hypertrophic cardiomyopathy (HCM) is a complex and relatively common genetic cardiac disease and it is the most common cause of sudden cardiac death in young people, including trained athletes. In a recent study using in vivo cardiac MR spectroscopy resting PCr/ATP ratio was diminished in patients with sarcomeric HCM, indicating reduced energy availability. Importantly patients with genotypic HCM who did not yet have hypertrophy had a similar degree of impairment of cardiac PCr/ATP ratio as do patients with marked hypertrophy, implying that the disturbance may be an early featu...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Symptomatic Hypertrophic Cardiomyopathy patients
- • 2. Abnormal Peak VO2
- • 3. No significant LVOT obstruction at rest (gradient \< 30mmHg)
- • 4. Sinus rhythm
- Exclusion Criteria:
- • 1. Abnormal LFT.
- • 2. Concomitant use of amiodarone
- • 3. Pre-existing evidence of peripheral neuropathy.
- • 4. Women of childbearing potential.
- • 5. Patients with ICD's will be excluded from the MR part of the study
About University Hospital Birmingham
University Hospital Birmingham is a leading academic medical center dedicated to advancing healthcare through innovative clinical research and trials. With a strong commitment to improving patient outcomes, the hospital integrates cutting-edge research with high-quality clinical care, leveraging its extensive expertise and state-of-the-art facilities. Collaborating with a network of healthcare professionals and researchers, University Hospital Birmingham aims to facilitate the development of new therapies and interventions, contributing to the advancement of medical knowledge and the enhancement of patient treatment options in a diverse range of specialties.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oxford, , United Kingdom
Birmingham, West Midlands, United Kingdom
London, , United Kingdom
Patients applied
Trial Officials
Michael Frenneaux, MD
Principal Investigator
University of Birmingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials